Cite
Liu Y, Wang S, Schubert ML, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2021;doi: 10.1002/ijc.33865.
Liu, Y., Wang, S., Schubert, M. L., Lauk, A., Yao, H., Blank, M. F., Cui, C., Janssen, M., Schmidt, C., Göllner, S., Kleist, C., Zhou, F., Rahfeld, J. U., Sauer, T., Schmitt, M., & Müller-Tidow, C. (2021). CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. International journal of cancer, . https://doi.org/10.1002/ijc.33865
Liu, Yi, et al. "CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells." International journal of cancer vol. (2021). doi: https://doi.org/10.1002/ijc.33865
Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2021 Nov 11; doi: 10.1002/ijc.33865. Epub 2021 Nov 11. PMID: 34766343.
Copy
Download .nbib